Anti-PVRIG Monoclonal Antibody

<strong>anti-PVRIG Monoclonal Antibody</strong>_x000D_ <strong>Catalog number:</strong> B2014657_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 10 µL_x000D_ <strong>Molecular Weight or Concentration:</strong> N/A_x000D_ <strong>Supplied as:</strong> Solution_x000D_ <strong>Applications:</strong> molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> 2-8 ¬∞C_x000D_ <strong>Keywords:</strong> CD112 receptor, CD112R, nectin-2 receptor, poliovirus receptor related immunoglobulin domain containing, poliovirus receptor-related immunoglobulin domain-containing protein, transmembrane protein PVRIG_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MŒ©-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Whelan S, Ophir E, Kotturi MF, Levy O, Ganguly S, Leung L, Vaknin I, Kumar S, Dassa L, Hansen K, Bernados D, Murter B, Soni A, Taube JM, Fader AN, Wang TL, Shih IM, White M, Pardoll DM, Liang SC. PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8(+) T-cell Function Cancer Immunol Res. 2019 Feb;7(2):257-268._x000D_ 2: Li Y, Zhang Y, Cao G, Zheng X, Sun C, Wei H, Tian Z, Xiao W, Sun R, Sun H. Blockade of checkpoint receptor PVRIG unleashes anti-tumor immunity of NK cells in murine and human solid tumors J Hematol Oncol. 2021 Jun 26;14(1):100._x000D_ 3: Sanchez-Correa B, Valhondo I, Hassouneh F, Lopez-Sejas N, Pera A, Bergua JM, Arcos MJ, Ba√±as H, Casas-Avil√©s I, Dur√°n E, Alonso C, Solana R, Tarazona R. DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy Cancers (Basel). 2019 Jun 23;11(6):877._x000D_ 4: Li J, Whelan S, Kotturi MF, Meyran D, D'Souza C, Hansen K, Liang S, Hunter J, Trapani JA, Neeson PJ. PVRIG is a novel natural killer cell immune checkpoint receptor in acute myeloid leukemia Haematologica. 2021 Dec 1;106(12):3115-3124._x000D_ 5: Lentz RW, Colton MD, Mitra SS, Messersmith WA. Innate Immune Checkpoint Inhibitors: The Next Breakthrough in Medical Oncology? Mol Cancer Ther. 2021 Jun;20(6):961-974._x000D_ 6: Conner M, Hance KW, Yadavilli S, Smothers J, Waight JD. Emergence of the CD226 Axis in Cancer Immunotherapy Front Immunol. 2022 Jun 24;13:914406._x000D_ 7: Murter B, Pan X, Ophir E, Alteber Z, Azulay M, Sen R, Levy O, Dassa L, Vaknin I, Fridman-Kfir T, Salomon R, Ravet A, Tam A, Levin D, Vaknin Y, Tatirovsky E, Machlenkin A, Pardoll D, Ganguly S. Mouse PVRIG Has CD8(+) T Cell-Specific Coinhibitory Functions and Dampens Antitumor Immunity Cancer Immunol Res. 2019 Feb;7(2):244-256._x000D_ 8: Zeng T, Cao Y, Jin T, Tian Y, Dai C, Xu F. The CD112R/CD112 axis: a breakthrough in cancer immunotherapy J Exp Clin Cancer Res. 2021 Sep 10;40(1):285._x000D_ 9: Birnbaum DJ, Picard M, Da Costa Q, Delayre T, Finetti P, Cabaud O, Agavnian E, De Rauglaudre B, Denicola√Ø E, Bertucci F, Mamessier E. PVRIG Expression Is an Independent Prognostic Factor and a New Potential Target for Immunotherapy in Hepatocellular Carcinoma Cancers (Basel). 2023 Jan 10;15(2):447._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/37542274">10: Dong Z, Xu M, Sun X, Wang X. Mendelian randomization and transcriptomic analysis reveal an inverse causal relationship between Alzheimer's disease and cancer J Transl Med. 2023 Aug 4;21(1):527. </a>_x000D_ _x000D_ <strong>Products Related to anti-PVRIG Monoclonal Antibody can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>